Abstract library

196 results for "Van Goor".
#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)
Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Victor Rodriguez-Freixinos
#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs
Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Thomas Yang Sun
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2864 Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Camilla Bardasi
Authors: Bardasi C, Caputo F, Santini C, Cerma K, ...
#3027 Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
Introduction: The 2018 SEER data indicates EP-PD-NEC morphology (SC vs. nSC) may impact patient outcomes.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Melissa Frizziero
#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#2885 Ectopic Neuroendocrine Carcinoma: An Occult Source of ACTH
Introduction: About 250 cases of ectopic ACTH-producing neuroendocrine carcinoma (ACTH-NEC) have been reported; however metastatic ACTH-NEC of unknown primary is very rare. Usually are characterized by having a large cell, small cell, poorly differentiated or anaplastic cell, and Ki-67 index between 40-90%.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Deyanira González Devia
#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance
Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Chiara Liverani
#2713 The Economic Impact to Patients with Neuroendocrine Tumours
Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Assoc Prof David Wyld
Authors: Wyld D, Elliott T, Wakelin K, Leyden S, ...